Rylova et al. utilized [89Zr]Zr-DFO-AC-10 antibodies for detecting CD30-positive human lymphomas and demonstrated their potential to effectively target and visualize CD30 expression in lymphomas within these human Karpas 299 tumours (CD30-positive model) or A-431 tumours (CD30-negative model), with the highest uptake in CD30-positive tumours (ROI: 37.9 ± 8.2%ID/g), 72 h post-injection. This evidence concerns the gene TNFRSF8 and neoplasm.